Investors expect Luyan Pharma Co.,Ltd.'s limited growth rate...
Investors expect Luyan Pharma Co.,Ltd.'s limited growth rates to continue, contributing to its low P/E ratio. The recent medium-term earnings trends, worse than market expectations, also play a part. Investors believe the potential for earnings improvement doesn't justify a higher P/E ratio.
Earnings Working Against Luyan Pharma Co.,Ltd.'s (SZSE:002788) Share Price Following 29% Dive
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment